Cambridge, United Kingdom – 19 January 2023 - Congenica, a UK-based digital health company that enables the rapid analysis and interpretation of genomic data, is adding a novel CE-IVD Precision Oncology Solution to its Clinical Decision Support (CDS) Platform.
Despite advances in biomarker-based drug approvals and availability, precision oncology medicine is still largely underutilised by clinicians worldwide. Congenica Oncology aims to democratise patient access by providing a fully automated and cost-effective end-to-end solution aimed at transforming the usability and scalability of genomic data for routine oncology clinical practice.
Congenica’s novel platform enables unbiased, evidence-based interpretation of NGS data with focus on actionable insights for rapid treatment decisions powered by NCCN, ESMO, NICE and SMC best practice guidelines with authorised therapeutic assertions from the FDA, EMA, and MHRA.
The Early Access Program, which will be available for European customers from 19 January 2023, will initially support Illumina’s TSO500 panels. Additional commercial as well as custom panels will be added for launch later in the year.
Alistair Johnson, Chief Professional Services Officer at Congenica, said: “The expansion of Congenica’s Clinical Decision Support (CDS) Platform into Oncology is a significant step for Congenica. Our universal platform is ideally placed to support genome-based analyses across a wide range of disease areas. Our novel Precision Oncology Solution offers a scalable, fully automated future-proof end-to-end solution that will drive precision medicine and deliver highest quality patient support.”
For further information, please visit Congenica Oncology Early Access Program.
